Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen

Abstract

A subcutaneous (SC) formulation has been developed for the humanized monoclonal antibody (mAb) trastuzumab as an alternative to established intravenous (IV) infusion. The ready-to-use liquid SC formulation is injected as a fixed dose in approximately 5 min, which is expected to increase patient’s convenience, reduce pharmacy preparation time, and administration costs overall.

The trastuzumab dose as well as the dose of recombinant human hyaluronidase (rHuPH20), an enzyme that enables SC administration of volumes larger than 2 mL, was selected based on nonclinical xenograft, pharmacology, and pharmacokinetics mouse and minipig studies.

The basic assumption for bridging from the IV to the SC regimen was that comparable trastuzumab serum trough concentrations would result in comparable efficacy. This hypothesis is confirmed by the results from the Phase 3 study in the neo-adjuvant/adjuvant setting. The safety profiles of the trastuzumab SC and IV formulations are comparable and consistent with the known safety profile of trastuzumab.

Key words

subcutaneous - trastuzumab - injection device - dose finding - nonclinical - clinical

• References

• 1 Clifford A, Hudis MD. Trastuzumab, Mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51
• 2 Bystricky B, Okines AFC, Cunningham D. Targeting HER-2 in gastric cancer – incorporation of trastuzumab into the treatment of operable disease. Gastrointestinal Cancer: Targets and Therapy 2011; 1: 41-52
• 3 Poorter RL, Lauw FN, Bemelman WA et al. Complications of an Implantable Venous Access Device (Port-A-Cath^®) During Intermittent Continuous Infusion of Chemotherapy. Eur J Cancer 1996; 32: 2262-2266
• 4 Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol 2009; 27 (29) 4858-4864
• 5 Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353 (16) 1659-1672
• 6 Bedell CH. A changing paradigm for cancer treatment: The advent of new oral chemotherapy agents. Clin J Oncol Nurs 2003; 7 (Suppl. 06) 5-9
• 7 Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115
• 8 Laino C. Oral chemotherapy plus trastuzumab found safe, effective for breast cancer. Oncology Times 2009; 31 (09) 28-30
• 9 Schweighofer C, Wendtner C. First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. OncoTargets and Therapy 2010; 3: 53-67
• 10 Fasth A, Nystroem J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol 2008; 28: 370-378
• 11 Barber N, Hoffmeyer U. Comparison of the cost-effectiveness of administering heparin subcutaneously or intravenously for the treatment of deep vein thrombosis. Annals of The Royal College of Surgeons of England 1993; 75: 430-433
• 12 Kivitz A, Cohen S, Dowd JE et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the touch trial. Clin Ther 2006; 28: 1619-1629
• 13 Akpinar RB, Celebioglu A. Effect of injection duration on bruising associated with subcutaneous heparin: a quasi-experimental within-subject design. International Journal of Nursing Studies 2008; 45: 812-817
• 14 Jorgensen JT, Romsing J, Rasmussen M et al. Pain assessment of subcutaneous injections. The Annals of Pharmacotherapy 1996; 30: 729-732
• 15 Hunter J. Subcutaneous injection technique. Nursing Standard 2008; 22: 41-44
• 16 Bittner B, Schmidt J. Subcutaneous Administration of Monoclonal Antibodies in Oncology as Alternative to Established Intravenous Infusion. Pharm Ind 2012; 74 (04) 638-643
• 17 Bookbinder LH, Hofer A, Haller MF et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. Journal of Controlled Release 2006; 114: 230-241
• 18 Watson D. Hyaluronidase. Br J Anaesth. 1993; 71: 422-425
• 19 Frost GI. Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opinion in Drug Delivery 2007; 4: 427-440
• 20 Chain E, Duthie E. Identity of hyaluronidase as spreading factor. Brit J Exper Pathol 1940; 21: 324-338
• 21 Pirrello RD, Ting Chen C, Thomas SH. Initial experiences with subcutaneous recombinant human hyaluronidase. J Palliat Med 2007; 10: 861-864
• 22 Thomas DR, Cote TR, Lawhorne L et al. Understanding clinical dehydration and its treatment. J Am Med Dir Assoc 2008; 9 (05) 292-301
• 23 Deputy Division Director’s Memorandum, NDA 21-859, 2005. Halozyme Therapeutics, Inc
• 24 Sanford M, McCormack PL. Ofatumumab. Drugs 2010; 70: 1013-1019
• 25 Bleeker WK, Munk ME, Mackus WJM et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 2008; 140 (03) 303-312
• 26 Ribas A, Hanson DC, Noe DA et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte – associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007; 12 (07) 873-883
• 27 Ricart AD, Tolcher AW, Liu G et al. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: A phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008; 14: 7924-7929
• 28 Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocrine-Related Cancer 2002; 9: 75-85
• 29 Baselga J, Phase II I. clinical trials of trastuzumab. Annals of Oncology 2001; 12 (Suppl. 01) S49-S55
• 30 Le XF, Mao W, Lu C et al. Specific Blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 2008; 7 (23) 3747-3758
• 31 Baselga J, Carbonell X, Castañeda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23 (10) 2162-2171
• 32 Bruno R, Washington CB, Lu JF et al. Population pharmacokinetics of trastuzumab in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 2005; 56 (04) 361-369
• 33 Fukushima Y, Charoin J, Brewster M et al. Population pharmacokinetic analysis of trastuzumab (Herceptin) based on three different dosing regimens. Abstracts of the Annual Meeting of the Population Approach Group in Europe 2007; 16 Abstr 1121
• 34 Mager D, Jusko W. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinetics Pharmacodynamics 2001; 28: 507-532
• 35 Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726
• 36 Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against humor tumor xenografts is superior to monotherapy. Clin Cancer Res 2005; 11: 5300-5308
• 37 Scheuer W, Friess T, Burtscher H et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69: 9330-9336
• 38 Bywaters EGL, Holborow EJ, Keech MK. Reconstitution of the dermal barrier after hyaluronidase injection. Br Med J 1951; 2 (4741) 1178-1183
• 39 Rose EH, Vistnes LM, Ksander GA. The panniculus carnosus in the domestic pig. Plast Reconstr Surg 1977; 59: 94-97
• 40 Zheng Y, Tesar DB, Benincosa L et al. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. mAbs 2012; 4 (02) March/April
• 41 Kirshner S. Immunogenicity of therapeutic proteins: a regulatory perspective. In: Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Tovey MG. (Ed.). John Wiley and Sons Inc.; NY, USA: 2011
• 42 Wynne C, Harvey V, Schwabe C et al. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol Published online 22. Feb. 2012;
• 43 Freireich EJ, Gehan EA, Rall DP et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey, and man. Cancer Chemother Rep 1966; 50: 219-244
• 44 Egorin MJ. Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target. Journal of Clinical Oncology 2003; 21 (02) 182-183
• 45 Bai S, Jorga K, Xin Y et al. A guide to rational dosing of monoclonal antibodies. Clinical Pharmacokinetics 2012; 51: 119-135
• 46 Mathijssen RH, de Jong FA, Loos WJ et al. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?. Oncologist 2007; 12 (08) 913-923
• 47 Ng CM, Lum BL, Gimenez V et al. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006; 23 (06) 1275-1284
• 48 Wang DD, Zhang S, Zhao H et al. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009; 49: 1012-1024
• 49 Jackisch C, Stroyakovskiy D, Muehlbauer S et al. Subcutaneous administration of trastuzumab in patients with HER2-positive early breast cancer: Results from the Phase III randomised, open-label, multi-centre neoadjuvant-adjuvant HannaH study. European Breast Cancer Conference (EBCC-8) 2012; Abstr 1BA
• 50 Dani B, Platz R, Tzannis ST. High concentration formulation feasibility of human immunoglobulin G for subcutaneous administration. J Pharm Sci 2007; 96: 1504-1517
• 51 Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci 2004; 93: 1390-1402
• 52 Adler M, Grauschopf U, Mahler HC et al. Subcutaneous anti-HER2 antibody formulations and uses thereof. Patent application US 2011/0044977 A1
• 53 Ratner M. Roche plans for more convenient-to-use Herceptin and Rituxan. Nature biotechnology 2010; 28 (04) 289